# Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention

> **NCT00189124** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Michigan** · enrollment: 13 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Dehydroepiandrosterone (DHEA)

## Key facts

- **NCT ID:** NCT00189124
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2005-12
- **Final completion:** 2006-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189124, "Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00189124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*